Bausch + Lomb CorpTSX:BLCOView on NYSE
- LAST PRICE20.5200
- TODAY'S CHANGE (%)0.2100 (1.0340%)
- Bid / Lots19.6700/ 2
- Ask / Lots20.9500/ 6
- Open / Previous Close20.5100 / 20.3100
- Day Range
- 52 Week Range
- Volume2,152
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLCO |
|---|---|---|
| 10:14 ET | 100 | 20.51 |
| 10:21 ET | 100 | 20.54 |
| 11:06 ET | 100 | 20.4 |
| 11:26 ET | 100 | 20.45 |
| 11:27 ET | 1000 | 20.45 |
| 12:16 ET | 100 | 20.335 |
| 12:25 ET | 100 | 20.37 |
| 01:51 ET | 300 | 20.52 |
Apr 22, 2024
DJ Bausch + Lomb Corp Is Maintained at Outperform by RBC Capital, from 1:29PM ET on Monday Apr 22, 2024 by Dow Jones
1:29PM ET on Monday Apr 22, 2024 by Dow Jones
Apr 18, 2024
Apr 15, 2024
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1, from 12:00PM ET on Monday Apr 15, 2024 by Dow Jones
12:00PM ET on Monday Apr 15, 2024 by Dow JonesPress Release: Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1, from 12:00PM ET on Monday Apr 15, 2024 by Dow Jones
12:00PM ET on Monday Apr 15, 2024 by Dow Jones
Mar 27, 2024
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting, from 7:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bausch + Lomb Corp | 5.2B | 0.0x | --- |
Company Information
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
Contact Information
- Headquarters
- 520 Applewood CrescentVAUGHAN, ON, Canada L4K 4B4
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.2B |
|---|---|
Revenue (TTM) | $4.1B |
Shares Outstanding | 351.4M |
Bausch + Lomb Corp does not pay a dividend. | |
Beta | --- |
EPS | $-0.74 |
Book Value | $19.52 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.3 |
Price/Cash Flow (TTM) | 38.9x |
Operating Margin | 3.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
